Últimas noticias sobre KYB CORP by KYB CORP. (OTC:KYBIF) Bolsa

KYB Corp is a Japanese automobile equipment manufacturer. The company products are divided into three branches hydraulic components (HC), automotive components (AC) and others. Through its operating segments, it provides various products such as shock absorber, suspension system, power steering, motion simulators, front fork and oil cushion unit, tunnel borers, vane pump and electronic parts. It also provides concrete mixer trucks, granule carriers, chipping vehicle and special function vehicles. The majority of the sales are accounted from the AC and HC products.

KYB CORP by KYB CORP.

News

General

Peabody Energy Announces It Is Reviewing All Options Regarding The Acquisition Of Steelmaking Coal Assets From Anglo American

Citigroup analyst Patrick Cunningham maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and lowers the price target from $95 to $74.

Price Target

Analyst Ratings

Citigroup Maintains Buy on DuPont de Nemours, Lowers Price Target to $74

Citigroup analyst Patrick Cunningham maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Neutral and lowers the price target from $42 to $32.

AXTA

Citigroup Maintains Neutral on Axalta Coating Systems, Lowers Price Target to $32

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Legal

JAZZ

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Nio Files 2024 Annual Report On Form 20-F For FY24 With The SEC

Citigroup analyst Christopher Allen maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Neutral and lowers the price target from $55 to $39.

Citigroup Maintains Neutral on Carlyle Group, Lowers Price Target to $39

Citigroup analyst Chris Allen maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $177 to $132.

Citigroup Maintains Buy on KKR, Lowers Price Target to $132

Citigroup analyst Chris Allen maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and lowers the price target from $190 to $137.

Citigroup Maintains Neutral on Blackstone, Lowers Price Target to $137

Citigroup analyst Chris Allen maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Buy and lowers the price target from $191 to $138.

Citigroup Maintains Buy on Apollo Global Management, Lowers Price Target to $138

<h3>Gainers</h3>
<ul>
<li>Aureus Greenway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock increased by 39.0% to $1.14 during Tuesday's after-market session. The company's market cap stands at $15.8 million. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) stock increased by 20.01% to $0.45. The company's market cap stands at $19.2 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares rose 11.11% to $2.0. The market value of their outstanding shares is at $9.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock increased by 9.53% to $0.17. The market value of their outstanding shares is at $68.1 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock increased by 9.03% to $4.79. The company's market cap stands at $18.5 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 6.27% to $1.02. The company's market cap stands at $19.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) stock decreased by 10.1% to $0.36 during Tuesday's after-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) stock fell 9.31% to $0.68. The company's market cap stands at $6.7 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) stock declined by 8.34% to $0.13. The market value of their outstanding shares is at $7.8 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) stock decreased by 6.23% to $2.41. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares fell 5.1% to $2.42. The company's market cap stands at $5.3 million. </li>
<li>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) stock declined by 4.77% to $1.2. The company's market cap stands at $64.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DXLG

LVLU

MKDW

QVCGA

RENT

RIME

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 55.6% to $0.24 during Tuesday's after-market session. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

AEMD

ANIX

ATNF

NAOV

NAYA

PTIX

REVB

SLRX

VERO

VINC

WORX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock increased by 14.9% to $3.4 during Tuesday's after-market session. The company's market cap stands at $2.0 million. </li>
<li>Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) stock increased by 10.52% to $1.68. The market value of their outstanding shares is at $24.8 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock increased by 10.2% to $1.08. The market value of their outstanding shares is at $27.5 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock rose 8.73% to $1.12. The company's market cap stands at $2.3 million. </li>
<li>Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) stock rose 8.04% to $8.33. The market value of their outstanding shares is at $642.0 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares increased by 7.52% to $2.0. The market value of their outstanding shares is at $66.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock declined by 11.5% to $0.84 during Tuesday's after-market session. The market value of their outstanding shares is at $15.1 million. </li>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) stock fell 10.68% to $0.42. The market value of their outstanding shares is at $11.0 million. </li>
<li>SKK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) stock fell 8.66% to $0.73. The market value of their outstanding shares is at $11.4 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares fell 6.57% to $1.14. The market value of their outstanding shares is at $61.8 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares decreased by 5.27% to $2.16. The market value of their outstanding shares is at $25.6 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) stock fell 5.14% to $0.68. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BAER

BEEM

EHGO

GLXG

IPDN

LICN

NEOV

PGHL

SGLY

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares moved upwards by 11.5% to $0.7 during Tuesday's after-market session. The company's market cap stands at $1.2 million. </li>
<li>WISeKey Intl Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock increased by 8.91% to $3.3. The company's market cap stands at $37.0 million. </li>
<li>Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares moved upwards by 7.66% to $7.3. The market value of their outstanding shares is at $216.8 million. The company's, Q3 earnings came out today. </li>
<li>Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) stock rose 7.63% to $4.37. The market value of their outstanding shares is at $4.3 million. </li>
<li>CommScope Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) shares rose 7.03% to $3.65. The market value of their outstanding shares is at $790.4 million. </li>
<li>Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) stock moved upwards by 5.89% to $23.5. The market value of their outstanding shares is at $5.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares fell 16.6% to $3.01 during Tuesday's after-market session. The company's market cap stands at $1.6 million. </li>
<li>SmartKem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) shares decreased by 10.75% to $2.41. The market value of their outstanding shares is at $8.7 million. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) stock declined by 10.52% to $4.81. The market value of their outstanding shares is at $8.5 million. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock decreased by 8.15% to $0.13. The company's market cap stands at $3.0 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares decreased by 7.66% to $2.17. The market value of their outstanding shares is at $2.5 million. </li>
<li>CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) stock fell 7.16% to $0.92. The company's market cap stands at $17.1 million. As per the press release, Q4 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

COMM

CWAN

CXAI

FOXO

NTRP

OBLG

SMTK

SVRE

VERB

WKEY

12 Information Technology Stocks Moving In Tuesday's After-Market Session

Citigroup analyst Christopher Allen maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and lowers the price target from $72 to $56.

Citigroup Maintains Buy on TPG, Lowers Price Target to $56

Redwire Corporation And ispace technologies-U.S. Sign MOU To Jointly Pursue Commercial Lunar Exploration And Science Missions For The NASA Commercial Lunar Payload Services Initiative And Other Customers

Citigroup analyst Christopher Allen maintains Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Buy and lowers the price target from $30 to $23.

Citigroup Maintains Buy on Blue Owl Capital, Lowers Price Target to $23

Across the recent three months, 14 analysts have shared their insights on Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Academy Sports, revealing an average target of $59.0, a high estimate of $70.00, and a low estimate of $53.00. Observing a downward trend, the current average is 6.78% lower than the prior average price target of $63.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146076_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Academy Sports. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Chukumba &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$77.00 &#x7C; 
&#x7C;Greg Melich &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $53.00&#x7C;$54.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $54.00&#x7C;$52.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$55.00 &#x7C; 
&#x7C;Brian Nagel &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $70.00&#x7C;$85.00 &#x7C; 
&#x7C;Seth Basham &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Anna Glaessgen &#x7C;B. Riley Securities &#x7C;Lowers &#x7C;Buy &#x7C; $65.00&#x7C;$70.00 &#x7C; 
&#x7C;Justin Kleber &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $55.00&#x7C;$60.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $55.00&#x7C;$58.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Academy Sports. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Academy Sports compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Academy Sports's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Academy Sports's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Academy Sports analyst ratings.</a>
<h2>Unveiling the Story Behind Academy Sports</h2>
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports &amp; recreation, and footwear.
<h3>Academy Sports: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Academy Sports's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -6.57% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Academy Sports's net margin excels beyond industry benchmarks, reaching 7.97%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Academy Sports's ROE stands out, surpassing industry averages. With an impressive ROE of 6.74%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.67%, the company showcases effective utilization of assets.
Debt Management: Academy Sports's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.89.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Academy Sports In The Eyes Of 14 Experts

In the latest quarter, 13 analysts provided ratings for Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high estimate of $75.00, and a low estimate of $42.00. A 2.54% drop is evident in the current average compared to the previous average price target of $59.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146066_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Harmony Biosciences Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $70.00&#x7C;$70.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Graig Suvannavejh &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $44.00&#x7C;$42.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Graig Suvannavejh &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $42.00&#x7C;$52.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$52.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $52.00&#x7C;$52.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harmony Biosciences Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Harmony Biosciences Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harmony Biosciences Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Harmony Biosciences Hldgs Better</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
<h3>Harmony Biosciences Hldgs: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Harmony Biosciences Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.51% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Harmony Biosciences Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 24.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Harmony Biosciences Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 7.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Harmony Biosciences Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.13%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.27, Harmony Biosciences Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views

Across the recent three months, 9 analysts have shared their insights on Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Owens-Corning, presenting an average target of $202.44, a high estimate of $235.00, and a low estimate of $176.00. This current average represents a 9.06% decrease from the previous average price target of $222.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146059_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Owens-Corning. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Bouley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $179.00&#x7C;$215.00 &#x7C; 
&#x7C;Collin Verron &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $183.00&#x7C;- &#x7C; 
&#x7C;Mike Dahl &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $212.00&#x7C;$212.00 &#x7C; 
&#x7C;Michael Rehaut &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $176.00&#x7C;$200.00 &#x7C; 
&#x7C;Matthew Bouley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $215.00&#x7C;$245.00 &#x7C; 
&#x7C;Mike Dahl &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $212.00&#x7C;$224.00 &#x7C; 
&#x7C;John Lovallo &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $235.00&#x7C;$245.00 &#x7C; 
&#x7C;Sam Reid &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $200.00&#x7C;$225.00 &#x7C; 
&#x7C;Garik Shmois &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $210.00&#x7C;$215.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Owens-Corning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Owens-Corning compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Owens-Corning's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Owens-Corning's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Owens-Corning analyst ratings.</a>
<h2>Unveiling the Story Behind Owens-Corning</h2>
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with four reportable segments: Composites, Insulation, Doors, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
<h3>Owens-Corning: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Owens-Corning's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 23.26%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Owens-Corning's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -9.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Owens-Corning's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.82%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Owens-Corning's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.77%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.11, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Owens-Corning's Future

During the last three months, 10 analysts shared their evaluations of GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for GXO Logistics, revealing an average target of $50.5, a high estimate of $66.00, and a low estimate of $40.00. A decline of 19.52% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146050_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive GXO Logistics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ariel Rosa &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $45.00&#x7C;$51.00 &#x7C; 
&#x7C;Lucas Servera &#x7C;Truist Securities &#x7C;Announces &#x7C;Hold &#x7C; $40.00&#x7C;- &#x7C; 
&#x7C;Scott Schneeberger &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $55.00&#x7C;$67.00 &#x7C; 
&#x7C;Thomas Wadewitz &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$72.00 &#x7C; 
&#x7C;Christian Wetherbee &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $44.00&#x7C;$60.00 &#x7C; 
&#x7C;J. Bruce Chan &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $66.00&#x7C;$74.00 &#x7C; 
&#x7C;Ravi Shanker &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$63.00 &#x7C; 
&#x7C;Brandon Oglenski &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $45.00&#x7C;$52.00 &#x7C; 
&#x7C;Rick Paterson &#x7C;Loop Capital &#x7C;Announces &#x7C;Hold &#x7C; $49.00&#x7C;- &#x7C; 
&#x7C;Patrick Creuset &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$63.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GXO Logistics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GXO Logistics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GXO Logistics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GXO Logistics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GXO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GXO Logistics analyst ratings.</a>
<h2>Delving into GXO Logistics's Background</h2>
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
<h3>Understanding the Numbers: GXO Logistics's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining GXO Logistics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.48% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): GXO Logistics's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.72, GXO Logistics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

KYB CORP by KYB CORP.

Noticias

Últimas noticias sobre KYB CORP by KYB CORP. (OTC:KYBIF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL